Evidence map›Paper›PMID 42538384›Full record

ArticleNature materials2026

A transferable gut microbiota-bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response.

Mengyu Chang, Yifan Wang, JongHoon Ha, Zoey R Neale, Nadim J Ajami, Laurence P Diggs, Ansel P Nalin, Yifan Ma, Shiyan Dong, Yasmine M Hoballah and 21 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Microbiota matter.Nature materials · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Mengyu Chang *Department of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan Wang *Department of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7387-0654
JongHoon Ha *Department of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zoey R Neale *Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nadim J Ajami *Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laurence P DiggsDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ansel P NalinDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan MaDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9371-4365
Shiyan DongDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2912-8895
Yasmine M HoballahPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abderrahman DayPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seong Dong JeongDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0003-5163-3924
Annette WuDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0005-8343-4748
Benjamin R SchrankDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8138-4250
Jared L EdwardsDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0008-7604-3441
Tianyu WangDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaotian WangDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0002-3330-3975
Yen-Tzu ChangDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chaoyang TangDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony J LimDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle Najarro TorresDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Weiye DengDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy PeitschDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maurice J DufilhoDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangeeta GoswamiDepartment of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dadi JiangDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0935-3908
Albert C KoongDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9824-1643
Padmanee SharmaDepartment of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.ORCID http://orcid.org/0000-0003-3438-7576
Wen JiangDepartment of Central Nervous System Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. wjiang4@mdanderson.org.ORCID http://orcid.org/0000-0001-9154-633X
Betty Y S KimDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bykim@mdanderson.org.ORCID http://orcid.org/0000-0001-6890-8355

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2001 to 2026
$28.3M
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7M
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2M
Harnessing ecDNA Detection in Antigen-Presenting Cells for Anti-Tumor ImmunityK08CA296776 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Benjamin R Schrank · 2025 to 2026
$278k
NCI NIH HHS K08 CA296776NCI NIH HHS P30 CA016672NIDDK NIH HHS P30 DK056338NIDDK NIH HHS U2C DK119886NIH HHS OT2 OD030544
6 · The paper itself

Abstract

The clinical efficacy of nanomedicines is often limited by hepatic sequestration, yet the endogenous programs determining this clearance state remain incompletely understood. Here we identify the gut microbiota as a regulator of nanomedicine biodistribution through bile-acid-associated programming of Kupffer cell phagocytic state. Using germ-free mice, microbial perturbation, faecal microbiota transplantation and multiomic profiling, we show that metronidazole remodels the gut microbial ecology and reprograms Kupffer cells into a reduced-uptake state, thereby suppressing hepatic clearance and enhancing the tumour accumulation of nanomedicines across multiple formulations and tumour models. Single-cell RNA sequencing reveals a shift in Kupffer cell populations from phagocytic to quiescent states, whereas metabolomic profiling identifies microbiota-dependent reductions in bile acid availability. Gut-bacteria-derived bile acids induce Kupffer cell phagocytosis, and faecal transfer transmits the low-clearance phenotype, defining a transferable gut microbiota-bile acid-Kupffer cell pathway affecting nanomedicine clearance.

Indexed as

Bile Acids and SaltsGastrointestinal MicrobiomeNanomedicineAnimalsFecal Microbiota TransplantationHumansKupffer CellsLiverMiceMice, Inbred C57BLPhagocytosisBile Acids and Salts

Identifiers

PMID42538384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.